Retatrutide Microdosing: What It Means

The whole page in four lines. The lowest maintenance dose ever tested in a retatrutide trial is 1mg once weekly, and it returned 8.7% over 48 weeks. The lowest maintenance dose in the pivotal Phase 3 trial is 4mg, and it returned 19.0% over 80 weeks with the lowest adverse event discontinuation rate in the entire programme, 4.1%, below the 4.9% recorded on placebo.

Below 1mg there is nothing. Not a small trial, not a subgroup, not a pharmacokinetic bridging study in an obesity population. Anything asserted about doses below the trial floor is extrapolation with no anchor, and this page will say so rather than dressing it up.

Microdosing is not a pharmacological category. It has no definition in any retatrutide protocol, publication or regulatory document, and the sponsor has never used it. It arrived from other contexts entirely and was applied to this compound by people discussing it online.

In practice it gets used for three distinct ideas that are worth separating, because they have very different amounts of evidence behind them.

One: staying at an early escalation step. Every TRIUMPH-1 arm began at 2mg once weekly and stepped up every four weeks. Not climbing past an early step is sometimes described as microdosing. The dose in question was studied, but only as a transient rung, never as a maintenance dose with an efficacy readout attached to it.

Two: using the lowest studied maintenance dose. Choosing 4mg rather than 9mg or 12mg. This is the version with real data behind it, because 4mg is a full randomised arm of the pivotal trial with 80 weeks of efficacy and tolerability results.

Three: doses below anything ever tested. Fractions of a milligram, or spreading a weekly amount across multiple smaller administrations. This is the version with no evidence of any kind.

TRIUMPH-1 randomised 2,339 adults with obesity to 4mg, 9mg, 12mg or placebo, and ran 80 weeks with an extension to 104. All three active arms began at 2mg once weekly and moved up stepwise every four weeks to their assigned maintenance dose.

Two consequences follow that most low-dose discussion misses.

2mg and 6mg have no efficacy readout. They were rungs, occupied for four weeks at a time. No participant was maintained on either for 80 weeks, so no percentage can be attached to either. A page quoting a weight reduction figure for 2mg retatrutide is quoting something that does not exist.

The 4mg arm is the only arm that is both a step and a destination. It sits one escalation step above the shared start, which is why it is the natural subject of this whole conversation. The full escalation picture, including why the trials escalated at all, is in the titration filing.

Before Phase 3, the 2023 Phase 2 obesity trial published in the New England Journal of Medicine tested a lower ladder in 338 adults over 48 weeks. Its bottom rung was 1mg once weekly, and it is the lowest maintenance dose in the entire published record for this compound.

Read the 1mg row carefully, because it is the single most relevant piece of data on this page and almost nobody cites it. At one twelfth of the top dose, retatrutide still produced 8.7% mean body weight reduction over 48 weeks against 2.1% on placebo. That is a real, clearly separated effect, and it is roughly a third of what the 12mg arm achieved in the same trial.

It is also the clearest available demonstration that this compound is not all-or-nothing. A twelvefold reduction in dose did not eliminate the effect. It reduced it, substantially and predictably.

The Phase 2 numbers are historical and should never be used as the headline efficacy figure for retatrutide. The current top line is 28.3% at 80 weeks from TRIUMPH-1, with 30.3% in the 104-week extension, and the full picture is in the Phase 3 results filing. The 1mg row is cited here for what it is: the low end of a dose response curve.

If there is an evidence-based case for a lower-dose approach to retatrutide, it is the TRIUMPH-1 4mg arm, and it rests on two numbers rather than one.

19.0% over 80 weeks. To put that in proportion: it exceeds what semaglutide achieved in STEP 1, which was 14.9% over 68 weeks, and it sits below tirzepatide in SURMOUNT-1, which was 22.5% over 72 weeks. Those are three different trials of different lengths in different populations, so the comparison is not clean and should not be presented as one. It is still enough to show that the lowest Phase 3 retatrutide arm is not a token dose.

4.1% discontinuation for adverse events, against 4.9% on placebo. This is the more remarkable number. On the measure that counts people who left a trial they had volunteered for, the 4mg arm came in below the placebo arm. It is the lowest discontinuation figure anywhere in the programme.

That does not mean 4mg was symptom-free. Nausea in that arm ran 28.6% against 14.8% on placebo and diarrhoea 25.2% against 13.5%. The symptoms were present and clearly drug-related. What the discontinuation figure says is that at 4mg they were not severe enough to push people out at more than the ordinary background rate.

Laid out as increments, the ladder has a distinctive shape.

The first step delivers most of the effect and costs nothing measurable in discontinuation. The second delivers a substantial further gain at a moderate cost. The third delivers the least and costs the most, and is the only step where the tolerability increment exceeds the efficacy increment.

That shape is the honest, data-grounded version of the argument people are gesturing at when they use the word microdosing. Efficacy flattens as the dose climbs and tolerability does not.

There is a counterweight, and leaving it out would misrepresent the data. On averages, 12mg looks like a modest increment over 9mg. On the proportion of participants reaching a 30% or greater reduction, it is 45.3% against 37.9% at 9mg and 15.3% at 4mg. The averages compress a distribution that the dose is genuinely moving. Whether the average or the responder proportion is the right lens depends on the question being asked, and the trial data supports both readings.

One further correction to a common claim. It is often said that a lower dose simply takes longer to reach the same place. TRIUMPH-1 ran 80 weeks, long enough for all three arms to flatten, and they flattened at 19.0%, 25.9% and 28.3%. The 4mg arm did not converge on the others. The difference is in the ceiling, not only the pace.

Everything above describes doses that were randomised, administered on a fixed schedule, and measured. Here is what is not in the record.

No maintenance dose below 1mg has ever been studied. Not in Phase 2, not in Phase 3, not in the Phase 1b pharmacokinetic work in a way that produced weight outcomes.

No dosing interval other than weekly has ever been studied. Every published retatrutide trial used once-weekly administration. Splitting a weekly amount across several administrations, or extending the interval, has no trial data of any kind.

No trial escalated more slowly than four weeks. The four-week step interval is a fixed feature of the Phase 3 design.

No trial studied stopping at an escalation step. 2mg and 6mg were rungs with no maintenance readout attached.

The intuitive model is that a smaller dose produces a proportionally smaller effect, and there is genuine support for that in the record: the Phase 2 curve runs 8.7%, 17.1%, 22.8% and 24.2% across 1mg, 4mg, 8mg and 12mg, which is a clean and flattening dose response. But three features of this compound complicate the arithmetic.

Steady state takes weeks. The published half-life is approximately six days, from the Phase 1b pharmacokinetic study. Standard arithmetic puts steady state at four to five half-lives, so roughly 24 to 30 days at any fixed dose. Concentrations at a new dose are still climbing through about the first four weekly administrations. The full working is in the half-life filing. A short trial at a low dose tells you less than it appears to, because the exposure has not settled.

Three receptors, not one. Retatrutide is a triple agonist at the GIP, GLP-1 and glucagon receptors, described in the glucagon receptor filing. There is no basis in the published record for assuming those three engage in fixed proportion as the dose falls, and if they do not, a low dose is not simply a weaker version of a high one. Nobody has published the data that would settle it.

Measurement error rises as doses shrink. Smaller volumes drawn from a reconstituted vial carry proportionally larger error, and reconstitution arithmetic is where most practical mistakes in this area actually happen. That is a handling question rather than a pharmacology one, and it is what the reconstitution calculator and the bacteriostatic water guide exist for.

Retatrutide is not approved in any market and is not registered with FDA Philippines. Lilly stated in July 2026 that it plans to submit a Biologics License Application to the US FDA in Q1 2027. Until an approval exists there is no official dosing information for any dose, high or low, which is the underlying reason this question is answered by short video rather than by a label.

In this country the compound exists as research material, which is the subject of the retatrutide Philippines filing, with the regulatory background in the FDA Philippines guide and handling in a tropical climate in the storage filing.

1. [01]TrialLilly · TRIUMPH-1 readout, 21 May 2026

   Pivotal obesity trial, n=2,339 over 80 weeks. Source for 19.0% at 4mg, 25.9% at 9mg, 28.3% at 12mg, 2.2% placebo, the 30.3% figure at 104 weeks, the responder proportions, and discontinuation at 4.1%, 6.9% and 11.3% against 4.9% placebo.

   investor.lilly.com · TRIUMPH-1 release
2. [02]TrialNEJM 2023 · Retatrutide Phase 2 obesity trial

   Jastreboff AM et al. N Engl J Med 2023;389(6):514-526. n=338 over 48 weeks. Source for the 1mg arm at -8.7%, the 4mg and 8mg combined arms, 12mg at -24.2% and placebo at -2.1%, and for the week 24 figures.

   nejm.org · 10.1056/NEJMoa2301972
3. [03]TrialLilly · TRIUMPH-2 and TRIUMPH-3 readout, 23 July 2026

   Source for the regulatory position, including the stated plan to submit a Biologics License Application to the FDA in Q1 2027.

   investor.lilly.com · TRIUMPH-2 and TRIUMPH-3 release
4. [04]ComparatorSURMOUNT-1 and STEP 1

   Tirzepatide 22.5% at 72 weeks in SURMOUNT-1 and semaglutide 14.9% at 68 weeks in STEP 1. Cited only for scale against the 4mg arm, in trials of different lengths and populations.

   See the head to head filings